How to choose a cord blood
bank in 2026.

Every cord blood bank in the United States meets two baseline requirements: FDA registration of the facility, and AABB accreditation of cellular therapy practices. Both are table stakes. Every bank on this list clears them.

What separates banks above the baseline is FDA licensure of a specific product (an active BLA, which means the FDA has reviewed and approved a cord blood product for medical use) and FACT accreditation. FACT is a cord-blood-specific quality audit run by the same organization that accredits the transplant centers that use cord blood in treatment. When a transplant center evaluates a unit, FACT accreditation means the bank and the clinical team operate under the same quality framework. StemCyte holds both: REGENECYTE® under US License 2280, and FACT accreditation since 2006. Cryo-Cell holds FACT since 2014 but no BLA. CBR and ViaCord hold neither tier above the baseline.

FDA registration of a facility is different from FDA licensure of a product. AABB accreditation of practices is different from FACT accreditation of cord-blood-specific quality systems.

Once cord blood arrives at a bank, it must be processed and reduced for cryopreservation. Different methods preserve different volumes and different cell populations. More preserved volume generally means more flexibility for future treatments, since some therapies require larger doses than others.

Two banks on this list stand out for distinct reasons. StemCyte's MaxCell® plasma-depletion processing preserves a 100 mL final volume, four times the industry standard. Cryo-Cell's PrepaCyte-CB shows the fastest published engraftment times among major processing methods, engrafting roughly four days quicker than hetastarch in peer-reviewed data (though the same study found no significant difference in overall patient survival). They optimize for different outcomes.

Volume preservation, engraftment performance, and cell viability all matter together. No single processing method is universally superior.

Most parents compare guarantee programs by the dollar amount. Cryo-Cell offers the highest on this list: $100,000 if PrepaCyte-CB-processed cord blood fails to engraft in transplant. Some banks advertise up to $110,000. That number is the least important thing on the page.

What matters is what the guarantee actually covers. Does it activate on engraftment failure, storage loss, or processing failure? Some only apply if the unit was processed under the bank's proprietary method, or if it met minimum cell-count thresholds at release. If your unit falls below dosing requirements for your child's body weight, most banks won't pay: the guarantee covers unexpected failure, not a unit used outside clinical standards. StemCyte's LifeSaver Guarantee adds something most do not: a replacement donor unit from the public registry, included at every plan tier.

Read the actual terms, not the marketing summary. The headline number is rarely the full story.

Cord blood banking is often the first time a parent commits to long-term newborn services. Some banks use this moment to offer genetic testing alongside the banking itself, ranging from screening panels to full whole genome sequencing.

ViaCord, through its parent company Revvity (formerly PerkinElmer), offers the deepest genetic testing on this list: whole genome sequencing of all 22,000 genes with analysis of 6,000 adult-onset or 2,500 childhood-onset gene panels, delivered via partner Genome Medical. CBR offers tiered newborn screening panels covering up to 1,500 genes. StemCyte offers Newborn Genetic Analysis (NGA), a 258-gene panel covering 200+ conditions. Cryo-Cell offers more limited options.

Genetic testing is independent of cord blood. Parents can pursue whole genome sequencing through a separate provider after banking with any company.